Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: A retrospective study

Clinical Endocrinology

Volumn 72, Issue 1, 2010, Pages 53-58

  Nachtigall, Lisa B ^a   Valassi, Elena ^a   Lo, Janet ^a   McCarty, David ^a   Passeri, Jonathan ^a   Biller, Beverly M K ^a   Miller, Karen K ^a   Utz, Andrea ^a   Grinspoon, Steven ^a   Lawson, Elizabeth A ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; ECHOCARDIOGRAPHY; FEMALE; GROUPS BY AGE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY VALVE INSUFFICIENCY; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVES; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 72249115799     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03608.x     Document Type: Article

References (20)

1. Schade, R., Andersohn, F., Suissa, S. et al. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29 38.
2. Zanettini, R., Antonini, A., Gatto, G. et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39 46.
3. Roth, B.L. (2007) Drugs and valvular heart disease. New England Journal of Medicine, 356, 6 9.
4. Lancellotti, P., Livadariu, E., Markov, M. et al. (2008) Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology, 159, 1 5.
5. Bogazzi, F., Buralli, S., Manetti, L. et al. (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice, 62, 1864 1869.
6. Kars, M., Delgado, V., Holman, E.R. et al. (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism, 93, 3348 3356.
7. Vallette, S., Serri, K., Rivera, J. et al. (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, 12, 153 157.
8. Wakil, A., Rigby, A., Clark, A. et al. (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology, 159, R11 R14.
9. Colao, A., Galderisi, M., Di Sarno, A. et al. (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism, 93, 3777 3784.
10. Devin, J.K., Lakhani, V.T., Byrd, B.F. 3rd. et al. (2008) Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine Practice, 14, 672 677.
11. Herring, N., Szmigielski, C., Becher, H. et al. (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology, 70, 104 108.
12. Zoghbi, W.A., Enriquez-Sarano, M., Foster, E. et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Journal of the American Society of Echocardiography, 16, 777 802.
13. Singh, J.P., Evans, J.C., Levy, D. et al. (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology, 83, 897 902.
14. Fox, E.R., Wilson, R.S., Penman, A.D. et al. (2007) Epidemiology of pure valvular regurgitation in the large middle-aged African American cohort of the Atherosclerosis Risk in Communities study. American Heart Journal, 154, 1229 1234.
15. Rothman, R.B., Baumann, M.H., Savage, J.E. et al. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102, 2836 2841.
16. Tan, L.C., Ng, K.K., Au, W.L. et al. (2008) Bromocriptine use and the risk of valvular heart disease. Movement Disorders, 24, 344 349.
17. Webster, J., Piscitelli, G., Polli, A. et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine, 331, 904 909.
18. Colao, A., Di Sarno, A., Sarnacchiaro, F. et al. (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism, 82, 876 883.
19. Choong, C.Y., Abascal, V.M., Weyman, J. et al. (1989) Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. American Heart Journal, 117, 636 642.
20. Klein, A.L., Burstow, D.J., Tajik, A.J. et al. (1990) Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. Journal of the American Society of Echocardiography, 3, 54 63.